[go: up one dir, main page]

AR132802A1 - 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer - Google Patents

2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer

Info

Publication number
AR132802A1
AR132802A1 ARP240101354A ARP240101354A AR132802A1 AR 132802 A1 AR132802 A1 AR 132802A1 AR P240101354 A ARP240101354 A AR P240101354A AR P240101354 A ARP240101354 A AR P240101354A AR 132802 A1 AR132802 A1 AR 132802A1
Authority
AR
Argentina
Prior art keywords
treatment
cyanothiophenes
cancer
derivatives
amino
Prior art date
Application number
ARP240101354A
Other languages
English (en)
Inventor
Joachim Broeker
Jason Abbott
Jianwen Cui
Stephen W Fesik
Andreas Gollner
Lorenz Herdeis
Tim Hodges
Andrew Little
Andreas Mantoulidis
Juergen Ramharter
Dhruba Sarkar
Kevin Sokol
Alex Waterson
Tobias Wunberg
Original Assignee
Boehringer Ingelheim Int
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Univ Vanderbilt filed Critical Boehringer Ingelheim Int
Publication of AR132802A1 publication Critical patent/AR132802A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención abarca compuestos de fórmula (1), donde R¹ᵃ, R¹ᵇ, R²ᵃ, R²ᵇ, Z, R³ a R⁵, el anillo A, el anillo B, p, q, V y W tienen los significados que se da en las reivindicaciones y en la memoria descriptiva, su uso como inhibidores de KRAS, composiciones farmacéuticas y preparaciones que contienen dichos compuestos y su uso como medicamentos / usos médicos, en especial como agentes para el tratamiento y/o la prevención de enfermedades oncológicas.
ARP240101354A 2023-05-30 2024-05-29 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer AR132802A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23175999 2023-05-30
EP23175994 2023-05-30

Publications (1)

Publication Number Publication Date
AR132802A1 true AR132802A1 (es) 2025-07-30

Family

ID=91375721

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101354A AR132802A1 (es) 2023-05-30 2024-05-29 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer

Country Status (4)

Country Link
US (1) US20250019385A1 (es)
AR (1) AR132802A1 (es)
TW (1) TW202511268A (es)
WO (1) WO2024246099A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025190342A1 (zh) * 2024-03-15 2025-09-18 苏州浦合医药科技有限公司 螺环化合物作为kras突变体抑制剂
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025261393A1 (en) * 2024-06-19 2025-12-26 Insilico Medicine Ip Limited Novel compounds as kras inhibitors and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
GEP201706774B (en) 2012-03-14 2017-11-27 Lupin Ltd Heterocyclyl compounds
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6577958B2 (ja) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
SI3359542T1 (sl) 2015-10-09 2021-08-31 Boehringer Ingelheim International Gmbh Spojine in derivati spiro(3H-indol-3,2'-pirolidin)-2(1H)-ona kot MDM2-P53 inhibitorji
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
EP3618818A4 (en) 2017-05-03 2020-12-09 Vivace Therapeutics, Inc. NON-CONDENSED TRICYCLIC COMPOUNDS
TWI870922B (zh) 2017-12-21 2025-01-21 德商百靈佳殷格翰國際股份有限公司 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AU2021285032A1 (en) * 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
PE20241356A1 (es) * 2021-12-01 2024-07-03 Boehringer Ingelheim Int Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer
TW202340209A (zh) * 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20250129095A1 (en) * 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) * 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4452975A1 (en) 2021-12-23 2024-10-30 Boehringer Ingelheim International GmbH 8-aza quinazolines as brain-penetrant sos1-inhibitors

Also Published As

Publication number Publication date
WO2024246099A1 (en) 2024-12-05
US20250019385A1 (en) 2025-01-16
TW202511268A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
AR132802A1 (es) 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
DOP2024000101A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
DOP2022000266A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CO2023005342A2 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
ECSP23030959A (es) Compuestos y su uso en el tratamiento del cáncer
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2019013893A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2024014215A2 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
AR131001A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
AR131414A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
AR131413A1 (es) Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso
ECSP24050199A (es) Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
CO2025001849A2 (es) Compuestos de imidazopiridina, preparación de los mismos y usos terapéuticos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure